Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma.

MLA

Müller, Michael, et al. “Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma.” Cancers, vol. 13, no. 17, Sept. 2021. EBSCOhost, https://doi.org/10.3390/cancers13174476.

APA

Müller, M., Rösch, L., Najafi, S., Gatzweiler, C., Ridinger, J., Gerloff, X. F., Jones, D. T. W., Baßler, J., Kreth, S., Stainczyk, S., Frese, K., Meder, B., Westermann, F., Milde, T., Peterziel, H., Witt, O., & Oehme, I. (2021). Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma. Cancers, 13(17). https://doi.org/10.3390/cancers13174476

Chicago

Müller, Michael, Lisa Rösch, Sara Najafi, Charlotte Gatzweiler, Johannes Ridinger, Xenia F Gerloff, David T W Jones, et al. 2021. “Combining APR-246 and HDAC-Inhibitors: A Novel Targeted Treatment Option for Neuroblastoma.” Cancers 13 (17). doi:10.3390/cancers13174476.